BANZEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BANZEL (BANZEL).
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
| Metabolism | Primarily hydrolyzed by carboxylesterases in the liver to inactive metabolites (CGP 47292). Minor metabolism via CYP450 enzymes (CYP2E1, CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19) but not significantly. |
| Excretion | Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion. |
| Half-life | Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days. |
| Protein binding | Approximately 34% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 0.7-1.0 L/kg, indicating distribution primarily into total body water. |
| Bioavailability | Absolute oral bioavailability is approximately 85% (high). Food increases Cmax and AUC by about 30-40%, but this is not considered clinically significant for dosing. |
| Onset of Action | Oral: Time to peak plasma concentration is 4-6 hours. Clinical onset of antiseizure effect may be observed within a few days of starting therapy. |
| Duration of Action | Due to a half-life of 6-10 hours, dosing is typically twice daily (every 12 hours) to maintain therapeutic concentrations. Duration of antiseizure effect is dependent on consistent dosing. |
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
| Dosage form | SUSPENSION |
| Renal impairment | CrCl < 30 mL/min: not recommended. CrCl 30-50 mL/min: maximum dose 400 mg twice daily. CrCl > 50 mL/min: no adjustment. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: start 200 mg twice daily, maximum 400 mg twice daily. Child-Pugh Class C: not recommended. |
| Pediatric use | Age ≥4 years: based on body weight. Starting dose: 10 mg/kg/day divided twice daily, titrate weekly by increments of 10 mg/kg/day to target maintenance 40 mg/kg/day (max 3200 mg/day). Max single dose: 1600 mg twice daily. |
| Geriatric use | No specific dose adjustment, but consider age-related renal impairment; monitor CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BANZEL (BANZEL).
| Breastfeeding | Rufinamide is excreted in human milk. The milk-to-plasma ratio is approximately 0.3. Breastfeeding is not recommended due to potential adverse effects in the infant, including somnolence, poor feeding, and weight loss. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of intrauterine growth restriction, neurodevelopmental delay, and hemorrhagic disease of the newborn due to vitamin K deficiency. |
■ FDA Black Box Warning
None
| Serious Effects |
Familial short QT syndrome (due to QT interval shortening). Hypersensitivity to rufinamide or any of its components.
| Precautions | May shorten QT interval; use caution with other drugs that shorten QT interval. Increased risk of suicidal thoughts/behavior. Monitor for hypersensitivity reactions (including DRESS). Central nervous system depression (dizziness, somnolence, ataxia). May decrease efficacy of hormonal contraceptives. Withdrawal seizures if abruptly discontinued. Dose adjustment needed in severe hepatic impairment. |
| Food/Dietary | BANZEL should be taken with food to increase bioavailability (Cmax increases by approximately 40% and AUC by 50% compared to fasting). Avoid grapefruit juice as it may alter drug metabolism. No other food interactions are documented. |
Loading safety data…
| Fetal Monitoring |
| Monitor serum drug levels during pregnancy to maintain therapeutic concentrations. Perform fetal ultrasound to assess for structural anomalies. Monitor for intrauterine growth restriction. Assess vitamin K status and administer vitamin K prophylaxis to the newborn. |
| Fertility Effects | Limited data; no known adverse effects on fertility in animal studies. In humans, no established impact on male or female fertility, but seizure control is important for reproductive health. |
| Clinical Pearls | BANZEL (rufinamide) is an antiepileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥1 year. Titrate slowly over 2-3 weeks to reduce risk of adverse effects. Monitor for shortened QT interval; contraindicated in familial short QT syndrome. Dose adjustments needed in severe hepatic impairment. May decrease efficacy of oral contraceptives containing ethinyl estradiol. Administer with food to enhance absorption. |
| Patient Advice | Take BANZEL exactly as prescribed with food to improve absorption. · Do not stop taking BANZEL suddenly; taper under medical supervision to avoid withdrawal seizures. · Inform your doctor if you have a heart condition, especially short QT syndrome. · Use effective contraception if applicable; BANZEL may reduce efficacy of oral contraceptives. · Monitor for dizziness, drowsiness, or coordination problems; avoid driving until you know how BANZEL affects you. · Report any unusual tiredness, fatigue, or signs of liver injury (yellowing skin/eyes, dark urine) immediately. |